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Abstract
Introduction: Despite healthcare providers’ growing awareness of pre-exposure prophylaxis (PrEP), prescription rates remain
low. PrEP is an efficacious HIV prevention strategy recommended for use with condoms but still protective in their absence.
Concern about the impact of PrEP on condom use and other risk behaviour is, nonetheless, among the barriers to prescription
commonly reported. To understand the implications of this concern for PrEP access, we examined how medical students’ will-
ingness to prescribe PrEP varied by patients’ condom use and partnering practices. We also assessed the perceived acceptabil-
ity of various reasons for condom discontinuation with PrEP.
Methods: An online survey was distributed to 854 medical students in the Northeastern US in 2015. Participants (n = 111)
were surveyed about their willingness to prescribe PrEP for each of six male patients who systematically differed in their
reported condom use (sustained use, sustained nonuse, or discontinuation with PrEP) and partnering practices (single male
partner with untreated HIV or multiple male partners of unknown HIV status). Participants also reported perceived acceptabil-
ity of four reasons for condom discontinuation: pleasure, sexual functioning, intimacy, and conception.
Results: Willingness to prescribe PrEP was inconsistent with patient risk: When the patient used condoms and planned to sustain
condom use, most participants were willing to prescribe PrEP – 93% if the patient had a single partner and 86% if the patient had
multiple partners. Fewer were willing to prescribe if the patient did not use condoms and planned to sustain nonuse (53% and 45%,
respectively) or used condoms but planned to discontinue use (27% and 28%). Significantly fewer participants were willing to pre-
scribe for a patient with multiple partners versus a single partner when the patient reported sustained condom use or sustained
condom nonuse.The number of participants who were willing to prescribe was similarly low for a patient with multiple partners ver-
sus a single partner when the patient reported that he planned to discontinue condom use. More participants accepted a patient dis-
continuing condoms for conception (69%) than for intimacy (23%), pleasure (14%), or sexual functioning (13%).
Conclusion: Medical students’ clinical judgments were misaligned with patient risk and suggest misconceptions or personal
values may undermine provision of optimal HIV prevention services.
Keywords: HIV; pre-exposure prophylaxis; healthcare disparities; prescriptions; health personnel; sexual minorities
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1 | INTRODUCTION
Pre-exposure prophylaxis (PrEP) is an efficacious HIV preven-
tion strategy [1]. US clinical guidelines cite condomless sex as
a key indicator of HIV risk and PrEP candidacy [2]. However,
many healthcare providers have expressed concern that con-
domless sex and other risk behaviours will increase if patients
are prescribed PrEP [3-16]. This sets up a potential “preven-
tion paradox:” Some providers may be more willing to
prescribe PrEP for patients who would use condoms concur-
rently with PrEP than for patients who would not, even
though the latter would be in greater need of PrEP absent
other forms of protection. In the current survey study of med-
ical students, we examined participants’ willingness to pre-
scribe PrEP for patients whose condom use and partnering
practices systematically differed. We also explored the per-
ceived acceptability of various reasons for patients discontinu-
ing condom use while taking PrEP.
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1.1 | Background
The updated US clinical guidelines [2] include recommenda-
tions to consider PrEP for sexually active, HIV-uninfected men
who have sex with men (MSM) who are not in a monogamous
relationship with a recently tested, HIV-negative man and
have engaged in recent condomless anal sex or recently had a
bacterial sexually transmitted infection (STI). The guidelines
also offer specific PrEP indications for people at risk for HIV
because of heterosexual activity or injection practices.
Despite the availability of clinical guidelines to support its
implementation, many providers have not prescribed PrEP. A
2015 national survey of over 1500 US primary care providers
found that only 7% had ever prescribed PrEP, even though
66% were aware of it [17]. One potential barrier to prescrib-
ing PrEP that providers have repeatedly reported is concern
about sexual risk compensation, which refers to patients
increasing their risk behaviour because of a perceived
decrease in HIV susceptibility while taking PrEP [3-16].
Although risk compensation behaviour was not commonly
reported by PrEP recipients in early research studies [1], a
number of PrEP users seen in clinical or community-based
practice settings have reported reducing their condom use
[18,19] or increasing the number of sexual partners with
whom they engage in condomless sex [20] after initiating
PrEP. PrEP candidates have identified diverse motivations for
reducing condom use while taking PrEP, including conception,
intimacy, and sexual pleasure [21-23].
Importantly, patients’ intentions and motivations surround-
ing condomless sex and other forms of risk compensation
behaviour are not clinically supported reasons for providers to
withhold PrEP from patients [24]. Although PrEP in combina-
tion with condoms might maximize sexual health protection by
preventing HIV, other STIs, and unwanted pregnancy, PrEP is
still protective against HIV in the absence of condoms. Cur-
rent scientific evidence suggests that the level of protection
that PrEP offers may outweigh the risk incurred by reductions
in condom use. For example, across two clinical settings, even
though 34% to 41% of the subset of PrEP patients surveyed
six to seven months after initiating PrEP reported reducing
their condom use, there were no seroconversions among the
combined sample of over 1500 patients [18,19]. Modelling
studies have corroborated this finding, suggesting that MSM
who are fully adherent to PrEP would maintain or increase
protection even if they reduced or discontinued condom use
[25,26]. Thus, medical evidence should lead providers to be no
less willing to prescribe PrEP for patients who engage in con-
domless sex (or plan to do so) than patients already protected
through condom use.
However, factors outside of medical evidence influence pro-
viders’ clinical decisions, including cognitive biases related to
patient characteristics [27]. Patients with identical presenting
problems or clinical requests can encounter differential treat-
ment based on seemingly irrelevant social and behavioural
characteristics. For example, providers have reported greater
willingness to prescribe opioids for pain relief when the
patient was injured during a ladder fall versus running from
the police [28]. To the extent that socially acceptable versus
socially stigmatized patient characteristics yield more favour-
able treatment, providers may be more willing to prescribe
PrEP for patients reporting continued condom use and
monogamy versus condomless sex and non-monogamy. This
discrepant treatment would undermine access for those most
in need, producing a prevention paradox.
1.2 | Study overview and objectives
In this survey study of medical students, we systematically
examined how PrEP clinical decision-making varied based on
patients’ reported sexual behaviour and motivations. First, we
assessed the effects of patient condom use (sustained use
versus sustained nonuse versus planned discontinuation with
PrEP), patient partnering practices (single male partner with
untreated HIV versus multiple male partners of unknown HIV
status), and their interaction on participants’ willingness to
prescribe PrEP. Specifically, participants rated their willingness
to prescribe PrEP for six HIV-negative male patients reporting
different combinations of condom use and partnering prac-
tices. If participants’ judgment aligned with medical evidence,
willingness to prescribe PrEP would be expected to corre-
spond to patient risk and be high for all six patients (because
all reported high-risk behaviour) and highest for patients
reporting condomless sex.
Second, we assessed the perceived acceptability of a patient
discontinuing condoms while taking PrEP when motivated by
conception versus other reasons – pleasure, sexual function-
ing, and intimacy. If participants’ judgment aligned with medi-
cal evidence, similar levels of acceptability would be expected
across reasons for condom discontinuation because discontin-
uation confers the same level of risk irrespective of reason.
2 | METHODS
This survey was conducted as part of a larger study. Proce-
dures described below have been reported elsewhere [29].
2.1 | Participants and procedures
In 2015, an online survey was distributed through internal
email lists to 854 medical students attending two medical
schools in the northeastern US. After consenting to partici-
pate, they were presented with background information about
PrEP (e.g. clinical efficacy) and supporting and opposing claims
for prescribing PrEP [30]; completed survey measures;
and received compensation. (See Data S1 for survey
background information, claims, and primary measures). The
Yale University Human Subjects Committee approved all pro-
cedures.
2.2 | Measures
2.2.1 | Willingness to prescribe PrEP
Participants rated their likelihood of prescribing PrEP to six
HIV-uninfected male patients. Patients’ reported behaviour
varied systematically according to a 3 (patient condom
use) 9 2 (patient partnering practices) within-subjects design,
such that a different combination of condom use and partner-
ing practices was described for each patient. The three con-
dom use categories included sustained condom use (uses
condoms and wants to continue using condoms with PrEP),
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sustained nonuse (does not use condoms and wants to con-
tinue not using condoms with PrEP), and planned discontinua-
tion (uses condoms and wants to stop using condoms with
PrEP). The two partnering practice categories were single part-
ner (in a monogamous relationship with a man who has HIV
and is not on treatment) and multiple partners (has sex with
multiple men whose HIV statuses he does not know).
Responses were recoded to create a dichotomous variable:
willing (“very” or “extremely” likely) versus not willing (“not at
all,” “a little bit,” or “somewhat” likely) to prescribe.
2.2.2 | Perceived acceptability of reasons for condom
discontinuation
Perceived acceptability of reasons for condom discontinuation
was assessed with one question: “Which of the following reasons
(if any) are acceptable reasons for a male patient to stop using
condoms while on PrEP? (check all that apply).” The four response
options were “because he finds sex without condoms to be more
physically pleasurable,” “because it is easier for him to maintain an
erection (stay hard) without condoms,” “because he feels closer
and more emotionally connected to his partner without condoms,”
and “because he is trying to conceive (get pregnant) with his
female partner.” These reasons for discontinuation represented
pleasure, sexual functioning, intimacy, and conception, respectively.
2.2.3 | Background characteristics
Participants reported sociodemographic information, including
age, race/ethnicity, gender, and sexual orientation. They also
reported their familiarity with PrEP (recoded as ever versus
never heard of PrEP), prior PrEP education (ever versus never
learned about PrEP as part of their medical school training),
and years of medical school completed.
2.3 | Analysis
Frequency distributions were calculated to characterize the
sample. Logistic regressions using generalized estimating equa-
tions (because of the within-subjects design) were performed
to examine additive and multiplicative (i.e. interactive or mod-
erated) effects of patient condom use and partnering practices
on willingness to prescribe PrEP, and to explore differences in
the perceived acceptability of condom discontinuation with
PrEP across four reasons. Analyses were repeated adjusting
for relevant background characteristics. We adjusted for age,
race/ethnicity, and prior PrEP education because these charac-
teristics were statistically related to one or both outcomes.
We adjusted for gender and sexual orientation given their
conceptual relevance.
3 | RESULTS
3.1 | Sample characteristics
Of the 854 medical students contacted, 169 enrolled in the
study and 111 completed all relevant measures, yielding a
13% response rate. As compared to the combined enrollment
statistics for the two medical schools, a larger percentage of
our study sample was White (62% of study sample versus
50% of all medical students; v2 [1] = 6.57, p = 0.01) and
female (66% versus 49%, respectively; v2 [1] = 13.02,
p < 0.01). Table 1 displays additional sample characteristics.
3.2 | Effects of patient condom use and partnering
practices on willingness to prescribe PrEP
Figure 1 displays the percentage of participants who were will-
ing to prescribe PrEP for each of the six hypothetical patients.
Tables 2 and 3 present additive and multiplicative effects. In the
initial (additive) regression model, condom use and partnering
practices were significantly associated with willingness to pre-
scribe PrEP. For the lowest-risk condom use category (sustained
condom use), most participants were willing to prescribe – 86% if
the patient was described as having multiple male partners and
93% if the patient had a single partner. Fewer were willing to pre-
scribe if the patient did not use condoms and planned to sustain
nonuse (45% if multiple partners, 53% if single partner) or used
condoms but planned to discontinue use (28% if multiple part-
ners, 27% if single partner). Overall, fewer participants were will-
ing to prescribe if the patient had multiple male partners versus a
single partner.
When the condom use x partnering practice interaction
term was added to the model, a significant interaction was
Table 1. Sample characteristics (n = 111)
n (%)
Age
<25 years 62 (55.9)
≥25 years 49 (44.1)
Race/ethnicity
White 69 (62.2)
Asian 30 (27.0)
Black/African American 7 (6.3)
Latino/Hispanic 3 (2.7)
Other 2 (1.8)
Gender
Female 73 (65.8)
Male 37 (33.3)
Other 1 (0.9)
Sexual orientation
Heterosexual 96 (86.5)
Bisexual 6 (5.4)
Gay/Lesbian 6 (5.4)
Other 3 (2.7)
Years of medical school completed
<1 (currently in first year) 24 (21.6)
1 (currently in second year) 37 (33.3)
2 (currently in third year) 27 (24.3)
≥3 (currently in fourth year+) 23 (20.7)
PrEP familiarity
Heard of PrEP 94 (84.7)
Never heard of PrEP 17 (15.3)
Prior PrEP education
Learned about PrEP in medical school 56 (50.5)
Did not learn about PrEP in medical school 55 (49.5)
PrEP, pre-exposure prophylaxis.
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detected. As shown in Table 4, follow-up logistic regression
analyses examining partnering practice effects stratified by
condom use revealed that fewer participants were willing to
prescribe if the patient had multiple partners versus a single
partner for two of three condom use categories: sustained
condom use and sustained condom nonuse.
3.3 | Differences in perceived acceptability of
reasons for condom discontinuation
Perceived acceptability of discontinuation varied across rea-
sons. Most participants (69%) considered conception an
acceptable reason for condom discontinuation, but fewer
accepted intimacy (23%), pleasure (14%), or sexual functioning
(13%; see Table 5).
4 | DISCUSSION
Medical students’ judgments were fundamentally misaligned
with medical evidence and suggested a prevention paradox,
whereby patients more in need of PrEP were less likely to
receive it. First, whereas the vast majority of participants
were willing to prescribe PrEP for a condom-using patient
who planned to keep using condoms while taking PrEP (lowest
risk condom use category), far fewer were willing to prescribe
PrEP for a patient who planned to stop using condoms or did
not use condoms to begin with. Second, although the partner-
ing practices of all patients suggested high risk, more partici-
pants were willing to prescribe when the patient was
described as having a single partner versus multiple partners
in most circumstances. Finally, even though condom discontin-
uation confers the same level of risk regardless of underlying
motivation, more participants were accepting of condom dis-
continuation for the purpose of conception than for intimacy,
pleasure, or sexual functioning. Collectively, these findings sug-
gest that PrEP-related clinical judgments may be vulnerable to
misconceptions – about PrEP, risk compensation, and/or stan-
dards of clinical practice – as well as other decisional influ-
ences, such as personal values surrounding condom use,
monogamy, and other aspects of sexuality.
The variation in participants’ willingness to prescribe PrEP
across condom categories is inconsistent with medical evi-
dence and only partially consistent with risk compensation
concerns. That fewer participants were willing to prescribe
PrEP for condom users planning to discontinue versus sustain
condom use may indeed reflect concern that condom discon-
tinuation with PrEP could increase HIV and other STI risk.
However, risk compensation concerns do not explain why
fewer participants were willing to prescribe PrEP for patients
28%
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Figure 1. Medical students’ willingness to prescribe pre-exposure prophylaxis (PrEP) for a hypothetical male patient. Patient condom use
and partnering practices were systematically varied using a 3 3 2 within-subjects design such that every participant rated six patients with
differing combinations of condom use and partnering practices. AORs represent the effect of partnering practice on willingness to prescribe
within each condom use category, adjusting for relevant background characteristics (age, race/ethnicity, gender, sexual orientation, and prior
PrEP education).
Table 2. Additive and interaction effects of condom use and
partnering practices on willingness to prescribe PrEP
Model
Unadjusted Adjusteda
Wald v2 df p Wald v2 df p
1. Additive effects
Condom use 100.42 2 <0.001 100.76 2 <0.001
Partnering
practice
5.79 1 0.016 6.21 1 0.013
2. Conditional and interaction effects
Condom use 95.73 2 <0.001 96.40 2 <0.001
Partnering
practice
5.67 1 0.017 5.85 1 0.016
Condom use
9 partnering
practice
6.63 2 0.036 6.57 2 0.037
PrEP, pre-exposure prophylaxis.
aModel adjusted for relevant background characteristics (age, race/
ethnicity, gender, sexual orientation, and prior PrEP education).
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already forgoing condoms. For most patients who do not use
condoms and plan to sustain nonuse – a category that many
actual PrEP users fall into [31] – HIV risk would decrease and
STI risk would be unlikely to change significantly if prescribed
PrEP. Greater reluctance to prescribe for condom nonusers
suggests that misconceptions about the effectiveness of PrEP
as a singular form of protection or values related to condoms
may have affected participants’ judgment. Notably, this finding
is inconsistent with prior studies of HIV care providers report-
ing condom nonuse to be an indicator of PrEP candidacy [32]
and reporting greater willingness to prescribe for MSM who
“sometimes” versus “always” use condoms [3], which may
reflect differences in training and experience.
The variation in participants’ willingness to prescribe PrEP
across partnering practices, whereby more participants were
willing to prescribe for patients with a single partner versus
multiple partners in most circumstances, suggests values
related to monogamy may have clouded participants’ judg-
ment. Alternatively, participants may have reasoned that
patients in an ongoing sexual relationship with a partner with
Table 4. Comparison of willingness to prescribe PrEP for patients with single versus multiple partners, stratified by condom use
Condom use category Partnering practice
Unadjusted Adjusteda
OR 95% CI p AOR 95% CI p
Sustained condom use Single partner (ref) - - - - - -
Multiple partners 0.46 0.23, 0.94 0.033 0.45 0.21, 0.95 0.035
Sustained nonuse Single partner (ref) - - - - - -
Multiple partners 0.72 0.56, 0.93 0.011 0.72 0.56, 0.93 0.011
Planned discontinuation Single partner (ref) - - - - - -
Multiple partners 1.05 0.76, 1.44 0.781 1.05 0.76, 1.45 0.782
PrEP, pre-exposure prophylaxis.
To probe the interaction, the effect of partnering practice was examined in separate models for sustained condom use, sustained nonuse, and
planned discontinuation.
aModel adjusted for relevant background characteristics (age, race/ethnicity, gender, sexual orientation, and prior PrEP education).
Table 5. Perceived acceptability of reasons a man may discontinue condoms while taking PrEP
Reason for discontinuing condoms
Participants reporting reason
to be acceptablea
Unadjusted Adjustedb
n (%) OR 95% CI p AOR 95% CI p
Conception (ref) 76 (68.5) - - - - - -
Intimacy 26 (23.4) 0.14 0.08, 0.24 <0.001 0.14 0.08, 0.24 <0.001
Pleasure 16 (14.4) 0.08 0.04, 0.15 <0.001 0.08 0.04, 0.14 <0.001
Sexual functioning 14 (12.6) 0.07 0.04, 0.13 <0.001 0.07 0.03, 0.13 <0.001
PrEP, pre-exposure prophylaxis.
aReasons were not mutually exclusive (participants could report multiple reasons to be acceptable).
bModel adjusted for relevant background characteristics (age, race/ethnicity, gender, sexual orientation, and prior PrEP education).
Table 3. Comparisons of willingness to prescribe PrEP across condom use categories and partnering practices (additive model)
Unadjusted Adjusteda
OR 95% CI p AOR 95% CI p
Sustained condom use (ref) - - - - - -
Sustained nonuse 0.14 0.08, 0.23 <0.001 0.14 0.09, 0.23 <0.001
Planned discontinuation 0.05 0.03, 0.09 <0.001 0.05 0.03, 0.09 <0.001
Single partner (ref) - - - - - -
Multiple partners 0.77 0.63, 0.95 0.016 0.76 0.61, 0.94 0.013
PrEP, pre-exposure prophylaxis.
aModel adjusted for relevant background characteristics (age, race/ethnicity, gender, sexual orientation, and prior PrEP education).
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untreated HIV were at higher risk because these patients
would potentially be exposed to HIV with every sexual event,
whereas patients with multiple partners of unknown HIV sta-
tus would only be exposed during some sexual events (since
some partners would likely be HIV-negative). The low number
of participants willing to prescribe PrEP for MSM planning to
discontinue condom use – whether they had one or multiple
partners – indicates particularly strong resistance to prescrib-
ing to condom users who intend to use PrEP as an alternative
(rather than supplemental) form of protection, irrespective of
partnering practices.
Higher acceptability of conception over all other reasons for
condom discontinuation with PrEP implicates personal values
related to sexuality and sexual orientation in participants’ judg-
ments. Given the high level of protection PrEP offers [33], a
property that participants were informed of prior to complet-
ing survey items, the magnitude of added HIV risk associated
with condom discontinuation among adherent patients is likely
to be negligible, particularly if prior condom use was subopti-
mal. The vast majority of participants regarded conception as
worthy of that risk, whereas only a third or less regarded
increased intimacy, pleasure, and sexual functioning as such.
This could suggest that participants placed greater value on
sex for reproductive purposes than for other reasons. Alterna-
tively, conception could have been perceived as a more tem-
porary period of discontinuation and, therefore, lower risk.
Either way, conception was the only reason of the four that
would not apply to same-sex couples. Thus, the primary rea-
sons for discontinuing condoms that MSM are likely to have
were unacceptable to most participants. Sexual prejudice has
previously surfaced in qualitative research on providers’ atti-
tudes towards PrEP [5,34], with some providers openly
acknowledging greater comfort prescribing PrEP to serodis-
cordant heterosexual couples trying to conceive as compared
to other patients [5].
4.1 | Implications for clinical training and guidelines
Provider training curricula and clinical guidelines surrounding
PrEP could help to prevent the observed inconsistencies
between PrEP-related clinical judgments and current medical
evidence from manifesting in clinical practice.
Within training curricula, common misconceptions related to
PrEP, risk compensation, and standards of practice should be
addressed directly. Providers should be informed of the rela-
tive risks associated with PrEP and condoms as singular and
dual forms of protection. Without explicit training about the
benefits of PrEP as a singular prevention option, providers
may rely on previously learned paradigms equating condom-
less sex with risk. In addition, alerting providers to the vulner-
ability of clinical judgment to medically unjustified personal
beliefs and biases could lead to greater vigilance and preven-
tive action in practice.
Current US federal guidelines cite condomless sex as an
indicator of PrEP eligibility and suggest that PrEP is unneces-
sary if consistent condom use can be achieved [2]. However,
the guidelines also suggest that PrEP is intended for concur-
rent use with condoms and that PrEP patients should be
counselled accordingly [2]. These mixed messages surrounding
the relevance of condom use to PrEP candidacy may foster
confusion. Express acknowledgement of PrEP’s value and
acceptability as a singular form of protection and comprehen-
sive recommendations for counselling patients who choose to
forgo condoms (or linkage to such recommendations [35])
should be included within clinical guidelines.
Both training curricula and clinical guidelines should instruct
providers to discuss PrEP with patients irrespective of
patients’ reported sexual behaviour [36]. Patients are not
always able or willing to report their sexual histories in an
accurate manner. If patients seeking PrEP believe that self-dis-
closing condomless sex or other risk behaviour to providers
would deter providers from prescribing PrEP, a belief sup-
ported by the current findings, they may be less inclined to
disclose. Nondisclosure would diminish providers’ capacity to
accurately assess patients’ HIV risk and other health needs
and decrease the quality of care and range of services pro-
vided. A patient-centered approach to sexual healthcare,
whereby providers support patients in making informed deci-
sions, should be practiced and communicated to patients. As
in HIV treatment, allied health professionals such as pharma-
cists and counselors may play key roles in PrEP education,
prescription, and maintenance, which can help to alleviate the
added demands placed on providers.
4.2 | Limitations
This survey was conducted with medical students, over half of
whom were in their first two years of medical school.
Although no statistically significant differences in willingness
to prescribe PrEP or perceived acceptability of condom dis-
continuation were detected based on years of medical school,
limited clinical instruction and experience reduce the general-
izability of our findings to the current health workforce. Par-
ticipants were recruited in the northeastern US; values
related to condoms, monogamy, and other dimensions of sexu-
ality could vary geographically. Generalizability is also limited
by the small sample size (n = 111), low response rate (13%),
and overrepresentation of White and female students relative
to the medical school populations sampled. Additionally, there
may have been systematic differences (e.g. in PrEP familiarity)
between survey completers and non-completers that we were
unable to characterize, further limiting the external validity of
our findings.
The PrEP-related background information and claims pre-
sented are also a potential limitation. Following a paradigm
used in prior research [30], we presented factual and empiri-
cally supported information (e.g. clinical efficacy [37]) as well
as claims supporting and opposing PrEP prescription. The
claims reflected providers’ self-reported attitudes in prior
research [38,39]. Supporting claims encouraged understanding
of patients’ decision to use PrEP without condoms, whereas
opposing claims introduced concerns about patient adherence
and drug resistance. Though intended to raise key considera-
tions in a relevant and balanced way, this preliminary material
may or may not represent messaging that providers would
ordinarily encounter or issues that would be salient when
making clinical decisions.
In our assessment of prescription willingness, the six
patients presented to participants were all MSM. The system-
atic differences in prescription willingness that we observed
across condom use categories may not generalize to other
groups for whom condomless sex is less taboo (e.g.
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heterosexuals). Future research could explore how sexual
practices intersect with patient sexual orientation and other
characteristics to affect prescription willingness.
Prescription willingness was reported based on hypothetical
cases. Hypothetical cases allow researchers to systematically
manipulate patient characteristics and make cleaner compar-
isons and stronger causal inferences. However, exploration of
provider reactions to patient self-disclosures in actual clinical
settings would provide a fuller picture.
The repeated-measures design, according to which each
participant rated all six patients, likely drew attention to the
differences across patients – namely, condom use and part-
nering practices, and little additional patient information upon
which to base prescription decisions was provided. One
might argue that this created an artificial emphasis on these
patient behaviours. However, the repeated decision-making is
not unlike clinical practice, in which providers consecutively
see patients and make judgments, and patient sexual beha-
viour is likely to be a central consideration when prescribing
PrEP regardless of access to additional patient information.
The design may also raise concern that participants were
able to discern the study’s purpose and potentially motivated
to respond in a socially desirable way. However, to the
extent that evidence-based practice is socially desirable, this
was not the response pattern observed. Additionally, the
ordering of hypothetical patient cases and reasons for con-
dom discontinuation was fixed. Study replication randomizing
the order of patient cases and discontinuation reasons would
strengthen the inferences made here. Use of a between-
groups design or presentation of additional information to
obscure the main research focus could also enhance general-
izability of findings.
Finally, we did not examine whether participants accurately
assessed the relative risk associated with condoms and PrEP
when used as singular and dual forms of protection, nor did
we directly measure personal values. Qualitative research may
be particularly valuable in exploring the misconceptions, val-
ues, and other cognitive and affective processes underlying
the clinical judgments reported here [27].
5 | CONCLUSIONS
PrEP and condoms in combination may offer the most com-
prehensive sexual health protection, but both offer protective
benefit and neither is infallible. Withholding PrEP due to con-
dom nonuse or non-monogamy is not medically justifiable and
runs counter to patients’ prevention needs. Our findings sug-
gest a need for PrEP training curricula and clinical guidelines
to explicitly support PrEP provision to patients who choose to
engage in condomless and non-monogamous sex and ensure
providers realize the value of PrEP as a singular form of HIV
protection.
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